FDMT vs. BCRX, VIR, TARS, NMRA, DNA, AUTL, RLAY, CGEM, SRRK, and PRME
Should you be buying 4D Molecular Therapeutics stock or one of its competitors? The main competitors of 4D Molecular Therapeutics include BioCryst Pharmaceuticals (BCRX), Vir Biotechnology (VIR), Tarsus Pharmaceuticals (TARS), Neumora Therapeutics (NMRA), Ginkgo Bioworks (DNA), Autolus Therapeutics (AUTL), Relay Therapeutics (RLAY), Cullinan Therapeutics (CGEM), Scholar Rock (SRRK), and Prime Medicine (PRME). These companies are all part of the "biological products, except diagnostic" industry.
BioCryst Pharmaceuticals (NASDAQ:BCRX) and 4D Molecular Therapeutics (NASDAQ:FDMT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, dividends, valuation, earnings and community ranking.
85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. Comparatively, 99.3% of 4D Molecular Therapeutics shares are owned by institutional investors. 4.4% of BioCryst Pharmaceuticals shares are owned by company insiders. Comparatively, 7.3% of 4D Molecular Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
4D Molecular Therapeutics has lower revenue, but higher earnings than BioCryst Pharmaceuticals. 4D Molecular Therapeutics is trading at a lower price-to-earnings ratio than BioCryst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
BioCryst Pharmaceuticals presently has a consensus target price of $14.00, suggesting a potential upside of 120.47%. 4D Molecular Therapeutics has a consensus target price of $44.22, suggesting a potential upside of 74.72%. Given 4D Molecular Therapeutics' higher probable upside, equities research analysts plainly believe BioCryst Pharmaceuticals is more favorable than 4D Molecular Therapeutics.
BioCryst Pharmaceuticals has a net margin of -58.69% compared to BioCryst Pharmaceuticals' net margin of -436.30%. 4D Molecular Therapeutics' return on equity of 0.00% beat BioCryst Pharmaceuticals' return on equity.
BioCryst Pharmaceuticals has a beta of 1.96, suggesting that its share price is 96% more volatile than the S&P 500. Comparatively, 4D Molecular Therapeutics has a beta of 2.94, suggesting that its share price is 194% more volatile than the S&P 500.
BioCryst Pharmaceuticals received 443 more outperform votes than 4D Molecular Therapeutics when rated by MarketBeat users. Likewise, 66.43% of users gave BioCryst Pharmaceuticals an outperform vote while only 65.38% of users gave 4D Molecular Therapeutics an outperform vote.
In the previous week, BioCryst Pharmaceuticals and BioCryst Pharmaceuticals both had 11 articles in the media. 4D Molecular Therapeutics' average media sentiment score of 1.27 beat BioCryst Pharmaceuticals' score of 0.80 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the media.
Summary
BioCryst Pharmaceuticals beats 4D Molecular Therapeutics on 9 of the 16 factors compared between the two stocks.
Get 4D Molecular Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for FDMT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FDMT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
4D Molecular Therapeutics Competitors List
Related Companies and Tools
